Zobrazeno 1 - 10
of 137
pro vyhledávání: '"S. Sutaria"'
Autor:
Dhruvitkumar S. Sutaria, Priya Agarwal, Kuan‐Chieh Huang, Dale R. Miles, Jacob Rotmensch, Heather Hinton, Jorge Daniel Gallo, Grozdana Rasuo, Rucha S. Sane
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 12, Pp 2989-2999 (2022)
Abstract Ipatasertib, an AKT inhibitor, in combination with prednisone and abiraterone, is under evaluation for the treatment of metastatic castration‐resistant prostate cancer (mCRPC). Hyperglycemia is an on‐target effect of ipatasertib. An open
Externí odkaz:
https://doaj.org/article/ca11a807d1734da0bdab9ef78990dd4e
Autor:
Ch. Srinivasarao, Sumanta Kundu, B. S. Yashavanth, S. Rakesh, K. N. Akbari, G. S. Sutaria, V. D. Vora, D. S. Hirpara, K.A Gopinath, G. R. Chary, J. V. N. S. Prasad, N. S. Bolan, B. Venkateswarlu
Publikováno v:
Carbon Management, Vol 12, Iss 1, Pp 13-24 (2021)
Productivity of cropland soils, especially in arid and semi-arid tropics of India rigorously declined due to increasing losses of soil organic carbon (SOC) over the past decades. In the present study, we examined a 16-years long term experiment with
Externí odkaz:
https://doaj.org/article/858e3bf5760a45b297a490327c72c1ae
Autor:
Dhruvitkumar S. Sutaria, Grozdana Rasuo, Adam Harris, Ryan Johnson, Dale Miles, Jorge Daniel Gallo, Rucha Sane
Publikováno v:
Pharmaceutics, Vol 14, Iss 10, p 2101 (2022)
Ipatasertib is a selective, small molecule Akt inhibitor that is currently being developed for the treatment of metastatic castration-resistant prostate cancer. Darolutamide is an androgen receptor (AR) inhibitor that is approved for the treatment of
Externí odkaz:
https://doaj.org/article/59a7a9e2fcc449b6b9b6b527905cc293
Autor:
Tae Hwan Kim, Xun Tao, Bartolome Moya, Yuanyuan Jiao, Kari B. Basso, Jieqiang Zhou, Yinzhi Lang, Dhruvitkumar S. Sutaria, Alexandre P. Zavascki, Afonso L. Barth, Stephanie M. Reeve, Herbert P. Schweizer, Deanna Deveson Lucas, John D. Boyce, Robert A. Bonomo, Richard E. Lee, Beom Soo Shin, Arnold Louie, George L. Drusano, Jürgen B. Bulitta
Publikováno v:
mBio, Vol 11, Iss 1 (2020)
ABSTRACT Poor penetration through the outer membrane (OM) of Gram-negative bacteria is a major barrier of antibiotic development. While β-lactam antibiotics are commonly used against Klebsiella pneumoniae and Enterobacter cloacae, there are limited
Externí odkaz:
https://doaj.org/article/15920c889cbe439dba2992e6e5cf4623
Autor:
Naoki Kotani, Justin J. Wilkins, Janet R. Wade, Steve Dang, Dhruvitkumar S. Sutaria, Kenta Yoshida, Sameer Sundrani, Hao Ding, Josep Garcia, Heather Hinton, Rucha Sane, Pascal Chanu
Publikováno v:
Cancer Chemotherapy and Pharmacology. 90:511-521
Purpose The exposure–response relationships for efficacy and safety of ipatasertib, a selective AKT kinase inhibitor, were characterized using data collected from 1101 patients with metastatic castration-resistant prostate cancer in the IPATential1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc64557c22e51a74560ae791a2e79af8
https://doi.org/10.1007/s00280-022-04488-2
https://doi.org/10.1007/s00280-022-04488-2
Autor:
Yuanyuan Jiao, Jun Yan, Michael Vicchiarelli, Dhruvitkumar S. Sutaria, Peggy Lu, Zeferino Reyna, Brad Spellberg, Robert A. Bonomo, George L. Drusano, Arnold Louie, Brian M. Luna, Jürgen B. Bulitta
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
Polymyxin B is a “last-line-of-defense” antibiotic approved in the 1960s. However, the population pharmacokinetics (PK) of its four main components has not been reported in infected mice. We aimed to determine the PK of polymyxin B1, B1-Ile, B2,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5feafbde13c8452ba67ec43eda832726
https://doi.org/10.1128/aac.00197-23
https://doi.org/10.1128/aac.00197-23
Publikováno v:
JCO Clinical Cancer Informatics.
PURPOSE Hyperglycemia is a major adverse event of phosphatidylinositol 3-kinase/AKT inhibitor class of cancer therapeutics. Machine learning (ML) methodologies can identify and highlight how explanatory variables affect hyperglycemia risk. METHODS Us
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f1661c49517fbe9a60deef06d490c24
https://doi.org/10.1200/cci.22.00168
https://doi.org/10.1200/cci.22.00168
Autor:
Dhruvitkumar S. Sutaria, Jinmai Jiang, Ola A. Elgamal, Steven M. Pomeroy, Mohamed Badawi, Xiaohua Zhu, Ryan Pavlovicz, Ana Clara P. Azevedo-Pouly, Jeffrey Chalmers, Chenglong Li, Mitch A. Phelps, Thomas D. Schmittgen
Publikováno v:
Journal of Extracellular Vesicles, Vol 6, Iss 1 (2017)
Extracellular vesicles (EVs) hold great potential as novel systems for nucleic acid delivery due to their natural composition. Our goal was to load EVs with microRNA that are synthesized by the cells that produce the EVs. HEK293T cells were engineere
Externí odkaz:
https://doaj.org/article/7c22fd9364884b21810f63bf8ad71308
Autor:
Xiaohua Zhu, Mohamed Badawi, Steven Pomeroy, Dhruvitkumar S. Sutaria, Zhiliang Xie, Alice Baek, Jinmai Jiang, Ola A. Elgamal, Xiaokui Mo, Krista La Perle, Jeffrey Chalmers, Thomas D. Schmittgen, Mitch A. Phelps
Publikováno v:
Journal of Extracellular Vesicles, Vol 6, Iss 1 (2017)
Extracellular vesicles (EVs) are under evaluation as therapeutics or as vehicles for drug delivery. Preclinical studies of EVs often use mice or other animal models to assess efficacy and disposition. However, as most EVs under evaluation are derived
Externí odkaz:
https://doaj.org/article/4a85104369e846e887541c15d16e4405
Autor:
Deanna Deveson Lucas, Cornelia B. Landersdorfer, Jürgen B. Bulitta, Tae Hwan Kim, Dhruvitkumar S. Sutaria, Amy Wright, John D. Boyce, Arnold Louie, Alicja J. Copik, Brian T. Tsuji, Herbert P. Schweizer, Michael H. Norris, Miranda J. Wallace, Jeremiah Oyer, Carolin Werkman, Suresh Dharuman, Eric D. LoVullo, Beom Soo Shin, Yinzhi Lang, Xun Tao, Rossie H. Jimenez-Nieves, Brett A. Fleischer, Yuanyuan Jiao, Robert A. Bonomo, Venkataraman Balasubramanian, Kari B. Basso, Eunjeong Shin, Marianne Mégroz, George L. Drusano, Victoria C. Loudon-Hossler, Keisha C. Cadet, Nagakumar Bharatham, Jieqiang Zhou, Stephanie M. Reeve, Bartolomé Moyá, Nirav Shah, Alaa R. M. Sayed, Richard E. Lee
Publikováno v:
Clinical Pharmacology & Therapeutics. 109:1000-1020
Multidrug-resistant bacteria are causing a serious global health crisis. A dramatic decline in antibiotic discovery and development investment by pharmaceutical industry over the last decades has slowed the adoption of new technologies. It is imperat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81d1fd44221b5ffb219142197006572e
https://doi.org/10.1002/cpt.2205
https://doi.org/10.1002/cpt.2205